sofosbuvir and ribavirin to treat hepatitis c virus genotype 4 infection in a 65-year-old patient with diabetes and low platelet: a case report

نویسندگان

nawfal r hussein department of internal medicine, college of medicine, university of duhok, duhok, iraq; department of internal medicine, college of medicine, university of duhok, duhok, iraq. tel: +96-475075002

چکیده

conclusions this report highlighted the importance and the safety of this regimen to treat hcv in the elderly. case presentation here, a case of chronic hcv was described in a 65-year-old female with diabetes and low platelet count. the patient was treated successfully by a combination of sofosbuvir+ ribavirin without major side effects. introduction hepatitis c virus (hcv) is a major public health problem especially in the elderly. the classical interferon/ribavirin regimen was unfavorable for elderly patents due to intolerability and adverse effects. more studies are needed about the safety profile of new direct-acting antiviral (daa) in the elderly.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report

BACKGROUND Ulcerative colitis is a lifelong, immunologically mediated disease. Direct-acting antivirals (DAAs) are now available for the treatment of chronic hepatitis C virus (HCV) infection. An interferon-free regimen appears useful, safe and effective for many patients for whom interferon-based treatment is contraindicated. CASE PRESENTATION We studied a 56-year-old treatment-naïve Japanes...

متن کامل

Pseudoporphyria in association with Hepatitis C virus infection: A case report

Pseudoporphyria is an uncommon bullous disease with similar clinical and histopathological findings to porphyria cutanea tarda, in the absence of detectable porphyrin elevation. We present a 34-year-old man with clinical and histological findings compatible with porphyria cutanea tarda, whose his urinary uroporphyrin was negative and we concluded that he was a case of pseudoporphyria. Concomita...

متن کامل

HEPATITIS B VIRUS INFECTION IN AN ANTI-HBC NEGATIVE PATIENT: A CASE REPORT

 ABSTRACT One of the best reliable markers of hepatitis B virus infection is antibodies to the core antigen (Anti-HBc). A first-time blood donor with HBsAg positivity was identified as an HBV carrier that was anti-HBc negative. The patient was followed for 24 months in order to investigate the evolution of his HBV serological profiles and HBVDNA (PCR). In the follow-up for 24 months, HBsAg, HBe...

متن کامل

A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection

BACKGROUND & AIMS In Taiwan, patients with chronic hepatitis C virus (HCV) infection are currently treated with pegylated interferon-alpha plus ribavirin, but interferon-based regimens can be poorly tolerated, especially by those with advanced liver disease and the elderly. Sofosbuvir, an oral nucleotide analogue inhibitor of HCV NS5B polymerase, is approved in Europe, the USA and Japan for tre...

متن کامل

Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection.

Reactivation of the hepatitis B virus (HBV) has been reported in patients with occult infection (OBI), i.e. HBV surface antigen (HBsAg) negative, HBV core antibody (anti-HBc) positive ± antibodies against HBsAg (anti-HBs) and detectable HBV DNA in serum or liver, receiving immunosuppressive or cytotoxic therapies. Recently, concerns have been raised regarding the risk of HBV reactivation in OBI...

متن کامل

Ledipasvir-sofosbuvir for hepatitis C genotype 4 infection.

In The Lancet Infectious Diseases, Anita Kohli and colleagues report the results of a single-centre, open-label cohort, phase 2a trial of a ledipasvir plus sofosbuvir fi xed-dose combination (FDC) for adult patients with genotype 4 hepatitis C virus (HCV). The primary endpoint was the proportion of patients achieving a sustained viral response at 12 weeks after the termination of study drugs (S...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
international journal of infection

جلد ۳، شماره ۴، صفحات ۰-۰

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023